{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:36:34Z","timestamp":1773174994706,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals. In this report, we describe two cases of SARS-CoV-2\u2013associated HUS treated with eculizumab, a C5-blocking monoclonal antibody reported to be remarkably effective in the treatment of HUS. Detailed biochemical and genetic complement system analysis is reported, and the prompt clinical response after C5 pharmacological blockade is documented. Our report provides the rationale and supports the use of terminal complement pathway inhibition for the treatment of SARS-CoV-2\u2013associated HUS.<\/jats:p>","DOI":"10.3389\/fphar.2022.842473","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T06:09:15Z","timestamp":1646028555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19"],"prefix":"10.3389","volume":"13","author":[{"given":"Valentina Fanny","family":"Leone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amantia","family":"Imeraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelita","family":"Condemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","article-title":"The State of Complement in COVID-19","volume":"22","author":"Afzali","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 Are Key Drivers of Microvascular Platelet Aggregation in Clinical Entities Spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2022","journal-title":"Blood Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1111\/ajt.12297","article-title":"Two Patients with History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations","volume":"13","author":"Alberti","year":"2013","journal-title":"Am. J. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an Emergency Treatment for Adult Patients with Severe COVID-19 in the Intensive Care Unit: A Proof-Of-Concept Study","volume":"28","author":"Annane","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"680567","DOI":"10.3389\/fimmu.2021.680567","article-title":"Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy","volume":"12","author":"Boudhabhay","year":"2021","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 Inflammation with Activation of the C5a-C5aR1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B8","unstructured":"Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University JHU)2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/infdis\/jiaa646","article-title":"Complement Activation in the Disease Course of Coronavirus Disease 2019 and its Effects on Clinical Outcomes","volume":"223","author":"de Nooijer","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41467-021-22781-1","article-title":"Human Kidney Is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"12","author":"Diao","year":"2021","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood.2021012752","article-title":"COVID-19 as a Potential Trigger of Complement-Mediated Atypical HUS","volume":"138","author":"El Sissy","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane Cofactor Protein Mutations in Atypical Hemolytic Uremic Syndrome (aHUS), Fatal Stx-HUS, C3 Glomerulonephritis, and the HELLP Syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12601","article-title":"Activation of the Alternative Pathway of Complement during the Acute Phase of Typical Haemolytic Uraemic Syndrome","volume":"181","author":"Ferraris","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","article-title":"Pulmonary and Cardiac Pathology in African American Patients with COVID-19: an Autopsy Series from New Orleans","volume":"8","author":"Fox","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated Intravascular Coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/jth.14975","article-title":"Coagulopathy in COVID-19","volume":"18","author":"Iba","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.kint.2020.05.025","article-title":"Thrombotic Microangiopathy in a Patient with COVID-19","volume":"98","author":"Jhaveri","year":"2020","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrmicro2279","article-title":"Shiga Toxins-Ffrom Cell Biology to Biomedical Applications","volume":"8","author":"Johannes","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1055\/s-0040-1712156","article-title":"Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both","volume":"46","author":"Levi","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.ekir.2021.03.897","article-title":"Kidney Thrombotic Microangiopathy after COVID-19 Associated with C3 Gene Mutation","volume":"6","author":"Mat","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","article-title":"The Case of Complement Activation in COVID-19 Multiorgan Impact","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of Complement Activation in aHUS and How to Monitor Eculizumab Therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, Atypical HUS and TTP Are All Diseases of Complement Activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical Hemolytic-Uremic Syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1161\/CIRCULATIONAHA.120.051828","article-title":"Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study","volume":"143","author":"Pellegrini","year":"2021","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"594849","DOI":"10.3389\/fimmu.2020.594849","article-title":"Complement Activation in Kidneys of Patients with COVID-19","volume":"11","author":"Pfister","year":"2020","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.1987.206","article-title":"HUS and TTP: Variable Expression of a Single Entity","volume":"32","author":"Remuzzi","year":"1987","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0261113","DOI":"10.1371\/journal.pone.0261113","article-title":"Eculizumab in Patients with Severe Coronavirus Disease 2019 (COVID-19) Requiring Continuous Positive Airway Pressure Ventilator Support: Retrospective Cohort Study","volume":"16","author":"Ruggenenti","year":"2021","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/ckj\/sfab024","article-title":"Successful Treatment of a COVID-19 Patient with Thrombotic Microangiopathy","volume":"14","author":"Safak","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal Coagulation Parameters Are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic Syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.kint.2020.10.030","article-title":"Atypical HUS Relapse Triggered by COVID-19","volume":"99","author":"Ville","year":"2021","journal-title":"Kidney Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","article-title":"Eculizumab in the Treatment of Shiga Toxin Haemolytic Uraemic Syndrome","volume":"34","author":"Walsh","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and Genetic Complement Alterations in Infection-Induced and Complement-Mediated Hemolytic Uremic Syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.842473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T06:09:19Z","timestamp":1646028559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.842473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":40,"alternative-id":["10.3389\/fphar.2022.842473"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.842473","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"842473"}}